Skip to main content

Table 4 The binding sites of highly antigenic peptides, with VaxiJen antigenicity scores >1, and the HLA-DRB1 binding alleles from analysis of the HPV-related high-frequency HLA-DRB1 in the general population

From: In silico analysis of HLA-1 and HLA-2 recognition of a designed recombinant human papillomavirus vaccine based on L1 protein HPV subtype 45

No.

Peptide

Start-End

Length

HLA-2 Binding Allele

VaxiJen Score

IC50

1

DLYIKGTSANMRET

301–314

14

HLA-DRB1*04:01

1.104

55

2

DLYIKGTSANMRETP

301–315

15

HLA-DRB1*04:01

1.091

56

3

TDLYIKGTSANMRET

300–314

15

HLA-DRB1*04:01

1.0182

54

  1. SMM core is shown in bold